Filing Details
- Accession Number:
- 0001127602-22-014951
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-05-18 16:26:46
- Reporting Period:
- 2022-05-16
- Accepted Time:
- 2022-05-18 16:26:46
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
313143 | Haemonetics Corp | HAE | Surgical & Medical Instruments & Apparatus (3841) | 042882273 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1674993 | Simon, Christopher | 125 Summer Street Boston MA 02110 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2022-05-16 | 832 | $56.10 | 191,327 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2022-05-16 | 26,041 | $0.00 | 217,368 | No | 4 | A | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | A | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-qualified Stock Option (Right to Buy) | Acquisiton | 2022-05-16 | 60,891 | $0.00 | 60,891 | $57.60 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
60,891 | 2029-05-16 | No | 4 | A | Direct |
Footnotes
- Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- This number includes unvested RSUs previously reported as well as 353 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 29, 2022.
- The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.
- Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
- Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.